5-chloro-2-(5-chlorothiophene-2-sulfonamido)benzoic acid | 871216-66-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2-(5-chlorothiophene-2-sulfonamido)benzoic acid
• 英文别名: 5-Chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]benzoic acid
• CAS: 871216-66-9
• 化学式: C₁₁H₇Cl₂NO₄S₂
• 分子量: 352.219
• InChiKey: ATSHNTORVCLZRM-UHFFFAOYSA-N

物化性质

• 沸点：
  530.2±60.0 °C(Predicted)
• 密度：
  1.722±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-chloro-2-(5-chlorothiophene-2-sulfonamido)benzoic acid 生成 Se-methyl-L-selenocysteine
  参考文献：
  名称：

  Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them

  摘要：

  本发明涉及式I的化合物，其中A1，A2，R1，R2，R3，X和n如权利要求中所定义，这些化合物是有价值的药物活性化合物，用于治疗和预防疾病，例如心血管疾病，如高血压，心绞痛，心力衰竭，血栓或动脉硬化。式I的化合物能够调节体内环磷酸鸟苷单磷酸（cGMP）的产生，并且通常适用于与cGMP平衡紊乱有关的疾病的治疗和预防。此外，本发明还涉及制备式I的化合物的方法，它们用于治疗和预防上述疾病以及制备用于此目的的药物，以及包含式I的化合物的制药制剂。

  公开号：

  US06881735B2
• 作为产物：
  描述：

  N-(3-chlorobenzoyl)-S-methyl-S-phenylsulfoximine 在 silver hexafluoroantimonate 、 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 水 、 copper diacetate 、 sodium hydroxide 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 30.0h， 生成 5-chloro-2-(5-chlorothiophene-2-sulfonamido)benzoic acid
  参考文献：
  名称：

  Sulfoximine Directed Intermolecular o-C–H Amidation of Arenes with Sulfonyl Azides

  摘要：

  The Ru(II)-catalyzed Intermolecular o-C-H amidation of arenes in N-benzoylated sulfoximine with sulfonyl azides is demonstrated. The reaction proceeds with broad substrate scope and tolerates various functional groups. Base hydrolysis of the amidation product provides the anthranilic acid derivatives and methylphenyl sulfoximine (MPS) directing group. This method Is successfully employed for the synthesis of HMR 1766.

  DOI：

  10.1021/ol400411v

文献信息

• Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
  申请人：Schindler Ursula

  公开号：US06881735B2

  公开（公告）日：2005-04-19

  The present invention relates to compounds of the formula I wherein A 1 , A 2 , R 1 , R 2 , R 3 , X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.

  本发明涉及式I的化合物，其中A1，A2，R1，R2，R3，X和n如权利要求中所定义，这些化合物是有价值的药物活性化合物，用于治疗和预防疾病，例如心血管疾病，如高血压，心绞痛，心力衰竭，血栓或动脉硬化。式I的化合物能够调节体内环磷酸鸟苷单磷酸（cGMP）的产生，并且通常适用于与cGMP平衡紊乱有关的疾病的治疗和预防。此外，本发明还涉及制备式I的化合物的方法，它们用于治疗和预防上述疾病以及制备用于此目的的药物，以及包含式I的化合物的制药制剂。
• Sulfoximine Directed Intermolecular <i>o</i>-C–H Amidation of Arenes with Sulfonyl Azides
  作者：M. Ramu Yadav、Raja K. Rit、Akhila K. Sahoo

  DOI：10.1021/ol400411v

  日期：2013.4.5

  The Ru(II)-catalyzed Intermolecular o-C-H amidation of arenes in N-benzoylated sulfoximine with sulfonyl azides is demonstrated. The reaction proceeds with broad substrate scope and tolerates various functional groups. Base hydrolysis of the amidation product provides the anthranilic acid derivatives and methylphenyl sulfoximine (MPS) directing group. This method Is successfully employed for the synthesis of HMR 1766.